Nemus Bioscience, Inc. announced an agreement with Albany Molecular Research Inc. for the development and manufacture of Nemus’s proprietary cannabinoid-based active pharmaceutical ingredients. The agreement will capitalize on AMRI’s process chemistry in the synthesis and formulation of Nemus’s proprietary prodrug of tetrahydrocannabinol. This molecule forms the basis of NB1111, Nemus’s compound being developed for the treatment of glaucoma.
“Advancing our lead therapeutic candidates into the API manufacturing stage is a major milestone for our company and is pivotal for initiating human studies,” commented Brian Murphy, MD, CEO-CMO of Nemus. “Cannabinoid-based therapies have the potential to revolutionize glaucoma therapy by not only lowering intraocular pressure, but by exerting a direct neuroprotective effect on the cells of the optic nerve, thereby preserving vision.” Go to NemusBioscience.com.